Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Trial SOUL (McGuire et al., NEJM 2025) Design Phase 3 / event-driven Population Adults with T2D + ASCVD or CKD Key result Oral semaglutide significantly reduced MACE vs placebo in high-CV-risk T2D
NNF18OC0052064)
Will Ipamorelin make me hungry
10.1159/000086406 88 LangP
complete metabolic panel
Lapatinib ditosylate, an approved anti-cancer drug, provides neuroprotective benefits in rotenone-induced PD rat models and holds promise for repurposing as a disease-modifying agent for PD
US$ 21.78
US$ 28.31
US$ 25.61
US$ 27.85
US$ 26.09
US$ 23.92
US$ 29.21
US$ 24.09
